000			04514nam a22007697a 4500
008			211101s20212021 xxu||||| |||| 00| 0 eng d
022			_a0002-9149
040			_aOvid MEDLINE(R)
099			_a34607645
245			_aComparison of Outcomes in Patients With COVID-19 and Thrombosis Versus Those Without Thrombosis.
251			_aAmerican Journal of Cardiology. 160:106-111, 2021 12 01.
252			_aAm J Cardiol. 160:106-111, 2021 12 01.
252			_zAm J Cardiol. 2021 Aug 28
253			_aThe American journal of cardiology
260			_c2021
260			_fFY2022
265			_saheadofprint
265			_sppublish
266			_d2021-11-01
268			_aAmerican Journal of Cardiology. 2021 Aug 28
269			_fFY2022
520			_aThe occurrence of venous thromboembolisms in patients with COVID-19 has been established. We sought to evaluate the clinical impact of thrombosis in patients with COVID-19 over the span of the pandemic to date. We analyzed patients with COVID-19 with a diagnosis of thrombosis who presented to the MedStar Health system (11 hospitals in Washington, District of Columbia, and Maryland) during the pandemic (March 1, 2020, to March 31, 2021). We compared the clinical course and outcomes based on the presence or absence of thrombosis and then, specifically, the presence of cardiac thrombosis. The cohort included 11,537 patients who were admitted for COVID-19. Of these patients, 1,248 had noncardiac thrombotic events and 1,009 had cardiac thrombosis (myocardial infarction) during their hospital admission. Of the noncardiac thrombotic events, 562 (45.0%) were pulmonary embolisms, 480 (38.5%) were deep venous thromboembolisms, and 347 (27.8%) were strokes. In the thrombosis arm, the mean age of the cohort was 64.5 +/- 15.3 years, 53.3% were men, and the majority were African-American (64.9%). Patients with thrombosis tended to be older with more co-morbidities. The in-hospital mortality rate was significantly higher (16.0%) in patients with COVID-19 with concomitant non-cardiac thrombosis than in those without thrombosis (7.9%, p <0.001) but lower than in patients with COVID-19 with cardiac thrombosis (24.7%, p <0.001). In conclusion, patients with COVID-19 with thrombosis, especially cardiac thrombosis, are at higher risk for in-hospital mortality. However, this prognosis is not as grim as for patients with COVID-19 and cardiac thrombosis. Efforts should be focused on early recognition, evaluation, and intensifying antithrombotic management for these patients. Copyright (c) 2021. Published by Elsevier Inc.
546			_aEnglish
650			_a*Coronary Thrombosis/pp [Physiopathology]
650			_a*COVID-19/pp [Physiopathology]
650			_a*Hospital Mortality
650			_a*Myocardial Infarction/pp [Physiopathology]
650			_a*Pulmonary Embolism/pp [Physiopathology]
650			_a*Stroke/pp [Physiopathology]
650			_a*Venous Thrombosis/pp [Physiopathology]
650			_aAged
650			_aAged, 80 and over
650			_aCoronary Thrombosis/co [Complications]
650			_aCOVID-19/co [Complications]
650			_aFemale
650			_aHumans
650			_aMale
650			_aMiddle Aged
650			_aMyocardial Infarction/co [Complications]
650			_aPulmonary Embolism/co [Complications]
650			_aSARS-CoV-2
650			_aStroke/co [Complications]
650			_aVenous Thrombosis/co [Complications]
651			_aMedStar Heart & Vascular Institute
651			_aMedStar Washington Hospital Center
656			_aAdvanced Cardiac Catheterization Research Fellowship
656			_aInterventional Cardiology Fellowship
657			_aJournal Article
700			_aAbramowitz, Jonathan
700			_aBen-Dor, Itsik
700			_aCase, Brian
700			_aChezar-Azerrad, Chava
700			_aForrestal, Brian
700			_aHashim, Hayder
700			_aMedranda, Giorgio
700			_aRappaport, Hank
700			_aRogers, Toby
700			_aSatler, Lowell F
700			_aShea, Corey
700			_aWaksman, Ron
700			_aWeintraub, William S
700			_aYerasi, Charan
700			_aZhang, Cheng
790			_aAbramowitz J, Ben-Dor I, Case BC, Chezar-Azerrad C, Forrestal BJ, Hashim H, Medranda GA, Rappaport H, Rogers T, Satler LF, Shea C, Waksman R, Weintraub WS, Yerasi C, Zhang C
856			_uhttps://dx.doi.org/10.1016/j.amjcard.2021.08.038 _zhttps://dx.doi.org/10.1016/j.amjcard.2021.08.038
942			_cART _dArticle
999			_c6721 _d6721